$33.21
0.21%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$33.21
+5.59 20.24% 1M
+6.68 25.18% 6M
+7.79 30.65% YTD
+8.91 36.67% 1Y
-0.61 1.80% 3Y
+25.30 319.85% 5Y
+23.26 233.77% 10Y
+23.26 233.77% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.07 0.21%
ISIN
US45258J1025
Symbol
IMVT
Industry

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$6.9b
Enterprise Value
$6.1b
Net debt
positive
Cash
$797.8m
Shares outstanding
206.3m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
9.4
Financial Health
Equity Ratio
89.1%
Return on Equity
-59.3%
ROCE
-77.0%
ROIC
-1,197.9%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$51.0m | -
SBC as % of FCF
-
SBC Growth 1Y
-6.5%
Share Count Growth 1Y
20.6%
Shareholder Yield
-20.6%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-565.6m
EBIT
$-566.0m
Net Income
$-538.2m
Free Cash Flow | ex SBC
$-414.3m | $-465.3m
Growth
Revenue | estimate
- | -
EBITDA
-20.2%
EBIT
-20.2%
Net Income
-20.4%
Free Cash Flow
0.9%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-2.6
FCF per Share
$-2.0
Short interest
19.9%
Employees
315
Rev per Employee
$0.0

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Immunovant Inc forecast:

18x Buy
78%
5x Hold
22%

Analyst Opinions

23 Analysts have issued a Immunovant Inc forecast:

Buy
78%
Hold
22%

Immunovant Inc Events

Past Events
NOV
9
Q2 2027 Earnings Call
8 days ago
AUG
6
Q1 2027 Earnings Call
3 months ago
APR
2
Special Call - Immunovant, Inc.
8 months ago
FEB
6
Q3 2026 Earnings Call
9 months ago
NOV
10
Q2 2026 Earnings Call
about one year ago

Financial data from Immunovant Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 68 68
19% 19%
-
- Research and Development Expense 459 459
19% 19%
-
-566 -566
20% 20%
-
- Depreciation and Amortization 0.39 0.39
3% 3%
-
EBIT (Operating Income) EBIT -566 -566
20% 20%
-
Net Profit -538 -538
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Neutral
GlobeNewsWire
●
8 days ago
IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA) In exploratory analyses, ACR50 and ACR70 response rates for patients who remained on IMVT-1402 600 mg in Period ...
Neutral
GlobeNewsWire
●
27 days ago
DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, wh...
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Dr. Venker
Employees 315
Founded 2018
Website immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today